|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.SE |
First Approval Date01 Jan 2000 |
|
MechanismANGPTL3 inhibitors |
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Pfizer Manufacturing Belgium BV
0 Patents (Medical) associated with Pfizer Manufacturing Belgium BV
100 Deals associated with Pfizer Manufacturing Belgium BV
100 Translational Medicine associated with Pfizer Manufacturing Belgium BV